Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrx’ Fortamet picks up exclusivity

Executive Summary

Andrx' Fortamet (metformin extended-release) awarded three years of Waxman/Hatch marketing exclusivity, company says June 7. Fortamet launched in May; FDA approved Andrx' 505(b)(2) application for the antidiabetic agent April 27 (1"The Pink Sheet" May 3, 2004, p. 16)...

You may also be interested in...



Andrx Fortamet Approved: Dosing Convenience Will Be Marketing Focus

Andrx will highlight the dosing convenience for Fortamet (metformin extended-release) in an effort to distinguish the antidiabetic agent from Glucophage XR and its generics

Medtech SMEs See Opportunities In UK Budget Of Few Surprises

Schemes and funding to support growth in the life sciences and medtech sectors featured in the UK government’s spring budget on 3 March.

Entries Open For The Global Generics & Biosimilars Awards 2021

Entries are now open for the Global Generics & Biosimilars Awards 2021, which will take place in Milan, Italy on 10 November.

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel